It appears there might be a slight typo in the ticker you provided. Based on Fintel's database and recent news, the ticker "CGTL.NAS" likely refers to Cognition Therapeutics, Inc. (NasdaqCM: CGTX).
Here's a summary of recent insights regarding CGTX:
Recent Analyst Activity
- Several analysts have maintained "Buy" ratings on CGTX recently. Chardan Capital and HC Wainwright & Co. have reiterated "Buy" ratings as recently as December 19, 2024, and May 27, 2025, respectively. B. Riley Securities upgraded its rating to "Buy" on December 19, 2024.1
- However, there have been recent decreases in the average one-year price target for CGTX. For example, the average price target was revised to $3.32 on July 17, 2025, down from previous targets.1
Financial Position and Funding
- As of June 30, 2025, Cognition Therapeutics reported $11.6 million in cash, cash equivalents, and restricted cash equivalents. The company has not generated positive cash flows from operations.2
- Management believes that existing cash, non-dilutive grants, and net proceeds from a March 2024 follow-on public offering will fund operating expenses and capital expenditures into the second quarter of 2026. This projection assumes no usage of the remaining At-The-Market (ATM) facility or the Lincoln Park Purchase Agreement.2
- As of September 30, 2025, there was $13.3 million of common stock remaining available for sale under the ATM, and $34.8 million available to draw from the Lincoln Park Purchase Agreement.3
- The company completed a follow-on public offering on March 14, 2024, selling 6,571,428 shares at $1.75 per share, generating approximately $11.9 million in net proceeds.4
Future Outlook
- Cognition Therapeutics expects to continue incurring significant expenses and net losses as it advances its product candidates through development and seeks regulatory approval. The company anticipates needing additional funding in the future to support operations, including potential commercialization.4
For more detailed financial information, you can explore the latest SEC filings for Cognition Therapeutics, Inc. (CGTX) on Fintel.
